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ABSTRACT
Complement is an innate immune system that most animal viruses must face during natural infections. Given that replication
and dissemination of the highly pathogenic Nipah virus (NiV) include exposure to environments rich in complement factors, we
tested the in vitro sensitivity of NiV to complement-mediated neutralization. Here we show that NiV was completely resistant to
in vitro neutralization by normal human serum (NHS). Treatment of purified NiV with NHS activated complement pathways,
but there was very little C3 deposition on virus particles. In in vitro reconstitution experiments, NiV particles provided time-
and dose-dependent factor I-like protease activity capable of cleaving C3b into inactive C3b (iC3b). NiV-dependent inactivation
of C3b only occurred with the cofactors factor H and soluble CR1 but not with CD46. Purified NiV particles did not support C4b
cleavage. Electronmicroscopy of purified NiV particles showed immunogold labeling with anti-factor I antibodies. Our results
suggest a novel mechanism by which NiV evades the human complement system through a unique factor I-like activity.
IMPORTANCE
Viruses have evolved mechanisms to limit complement-mediated neutralization, some of which involve hijacking cellular pro-
teins involved in control of inappropriate complement activation. Here we report a previously unknownmechanism whereby
NiV provides a novel protease activity capable of in vitro cleavage and inactivation of C3b, a key component of the complement
cascade. These data help to explain how an enveloped virus such as NiV can infect and disseminate through body fluids that are
rich in complement activity. Disruption of the ability of NiV to recruit complement inhibitors could form the basis for the devel-
opment of effective therapies and safer vaccines to combat these highly pathogenic emerging viruses.
The complement system constitutes a complex group of solubleand cell-associated proteins that together form an integral part
of the innate host defense against pathogens (reviewed in refer-
ence 1). Complement serves to link innate and adaptive immunity
to viruses through recognition of virions, direct neutralization of
infectivity, recruitment and stimulation of leukocytes, opsoniza-
tion by immune cells, and activation of T and B cell responses (1,
2). Complement activation plays important roles in viral patho-
genesis (e.g., see references 3 and 4) and has been the focus of
efforts to improve the effectiveness of vaccines and therapeutic
vectors. The goal of the work described here was to determine the
mechanism by which the paramyxovirus Nipah virus (NiV) is
resistant to complement-mediated inactivation by normal human
serum (NHS).
The complement cascade can be initiated through three main
pathways: the classical pathway, lectin pathway, or alternative
pathway (1, 2). These three pathways converge on a central com-
ponent, C3, which is activated by cleavage into the anaphylatoxin
C3a and into C3b, which can bind covalently to viral components
to aid in opsonization and phagocytosis. In the case of the alter-
native pathway, a C3 convertase composed of the complex C3bBb
is assembled, which carries out an amplification loop of further C3
cleavage. In the case of the lectin/classical pathway, C4 cleavage
into C4a and C4b leads to assembly of a second form of the C3
convertase consisting of C4bC2a. These two convertases can
propagate a signal leading to formation of the downstreammem-
brane attack complex (MAC), which is capable of lysing virus
particles or infected cells (reviewed in references 1 and 2).
Under normal conditions, inappropriate complement activa-
tion is regulated by a complex series of host proteins (5), with one
key regulatory step being at the formation and stability of the C3
convertases. For example, CD55 is a membrane-bound host pro-
tein that acts to dissociate the C3 convertase to prevent further
amplification. An alternative inhibitory mechanism involves the
host protease factor I, which blocks the formation of a stable C3
convertase through cleavage of C3b or C4b into inactive forms.
Factor I protease activity is highly specific for cleavage of only C3b
or C4b and is strictly dependent on a set of soluble or membrane-
bound host cofactors, such as factor H, CR1, CD46, or C4 binding
protein (C4BP) (6, 7).
The key C3 convertase complex is also a common target for
inhibition by many pathogenic microbes (8–10). For example,
some enveloped viruses recruit host cell membrane-bound regu-
lators into their envelope (e.g., CD55), which can then act to dis-
sociate C3 convertase complexes that form on the virion surface
(e.g., see references 11 and 12). Viruses can also block the C3
convertase by exploiting factor I protease to cleave C3b or C4b
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into the inactive forms. To date, no viruses have been reported to
directly recruit factor I. Instead, viruses can encode analogs or
mimics of host cell cofactors that act along with soluble factor I to
cleave complement proteins. This is evident in the case of vaccinia
virus VCP, a virally encoded mimic of normal cellular cofactors
that can function with factor I to cleave C3b (13). Alternatively,
cofactors that function with factor I can be supplied through re-
cruitment of host cell proteins, such as in the case of binding of
factorH to theWestNile virusNS-1 protein (14) or incorporation
of CD46 into a viral envelope (11, 12, 15).
We and others have previously shown that complement is
strongly activated by awide range of negative-strand RNA viruses,
including parainfluenza virus 5 (PIV5), mumps virus (MuV), ve-
sicular stomatitis virus (VSV), and Newcastle disease virus
(NDV). For each of these viruses, C3 has been shown to play an
essential role in effective in vitro neutralization by NHS (11, 15,
16). Conversely, many of these negative-strand RNA viruses ex-
ploit normal host cell inhibitors to evade complement pathways,
with the association of host cell inhibitors resulting in a delay but
not a complete inhibition of in vitro complement-mediated neu-
tralization (e.g., see references 11 and 15). However, the role of
complement in neutralization of many emerging highly patho-
genic paramyxoviruses is largely unknown.
Nipah virus (NiV) is an emerging zoonotic viral pathogen (ge-
nus Henipavirus, family Paramyxoviridae) that can cause severe
respiratory and neurological disease. NiV and the closely related
Hendra virus (HeV) are considered NIH category C priority
pathogens. NiV is of considerable importance, due to its high
mortality rate in human infections (70%), its pandemic poten-
tial through human-to-human transmission, and its potential im-
pact on farm economies (17–20). There are currently no approved
vaccines or therapeutics against NiV for human use (21). NiV is
thought to spread from fruit bats to humans, but person-to-per-
son transmission has become of increasing concern (22, 23). NiV
infection of humans can be systemic, where viral antigen can be
detected in a number of organs, including the respiratory tract,
neurons, lymphoid tissue, and endothelial cells lining blood ves-
sels (reviewed in reference 23). It is proposed thatNiV can dissem-
inate through blood in either a free form or through binding to
CD3 lymphocytes (24, 25). Because complement factors can be
derived from serum, cells lining the respiratory tract (26), or by
recruited lymphocytes, the sites of NiV infection andmechanisms
of dissemination suggest that complement is a highly relevant in-
nate immune pathway that NiV encounters during natural infec-
tions.
Given the role of complement in neutralization of a range of
different paramyxoviruses and that NiV infection involves expo-
sure to body fluids rich in complement activity, we have tested
whether NiV is sensitive to neutralization by human complement
pathways. We previously showed that VSV-based pseudotypes
containing theNiV glycoproteins are resistant to neutralization by
NHS in vitro (27). Here we have extended our work to demon-
strate that treatment of infectious NiV in vitrowithNHS results in
activation of complement pathways, but there is neither loss of
infectivity nor extensive deposition of C3 on virion particles. Fur-
thermore, our new results using functional assays that reconsti-
tuted C3b cleavage in vitro show that purified NiV provides a
unique factor I protease activity that is capable of inactivation of
C3b. Our data are the first report of a novel mechanism by which
a viral pathogen utilizes a virion-associated factor I-like protease
to evade human complement pathways.
MATERIALS AND METHODS
Cells, viruses, and neutralization assays. HeLa and Vero cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% heat-inactivated fetal calf serum (HyClone, Logan, UT), L-glu-
tamine, penicillin, and streptomycin at 37°C in a humidified CO2 incuba-
tor (5%). PIV5 was grown inMDBK cells, and its titer was determined on
CV-1 cells as described previously (11). NiV (Malaysia strain) and HeV
were kindly provided by the Special Pathogens Branch of the Centers for
Disease Control and Prevention, Atlanta, GA. For neutralization assays,
NiV was grown and its titer was determined on Vero cells. For biochem-
ical analyses of associated cofactors, NiV was grown in HeLa cells, which
are known to express CD55 andCD46 (11). The viral titer was determined
by plaque assay on Vero cells.
NiV andHeVwere purified as described previously (11). Briefly, HeLa
cells were infected with virus at amultiplicity of infection (MOI) of 0.1. At
5 days postinfection, the supernatant was collected and clarified by low-
speed centrifugation. Clarifiedmediumwas then layered over a 20% glyc-
erol cushion in NTE buffer (100 mM NaCl, 10 mM Tris-Cl [pH 7.4], 1
mM EDTA), and virus was concentrated by ultracentrifugation (23,000
rpm for 5 h at 12°C in an SW28 rotor [Beckman Coulter, Fullerton, CA]).
Concentrated virus was further purified by centrifugation on a 20 to 60%
sucrose gradient (23,000 rpm for 1 h at 12°C in an SW28 rotor), and the
banded virus was collected, dilutedwithNTE buffer, pelleted (23,000 rpm
for 5 h at 12°C), and resuspended in 1 ml of DMEM, and aliquots were
stored at80°C. Aliquots were inactivated on dry ice by gamma irradia-
tion (5 megarads). All infectious work was performed in a class II biolog-
ical safety cabinet (BSC) in a biosafety level 4 (BSL4) laboratory at the
Galveston National Laboratory, University of Texas Medical Branch.
For NiV neutralization assays, 2-fold serial dilutions (1:5 to 1:80) of
normal human serum (NHS) or heat-inactivated (HI) NHS serum were
incubated with 100 PFU of NiV for 1 h at 37°C. Negative-control samples
were incubated with phosphate-buffered saline (PBS) alone. NiV-specific
mouse immune serum was used as a positive control in this assay. All
dilutions of the sera and virus were made in DMEM without fetal bovine
serum (FBS). Following the 1-h incubation, each serum-virus mixture
was added in triplicate to Vero cells and incubated for another hour at
37°C. Following adsorption, the inoculum was removed, and the cells
were overlaid with 0.8% agarose–minimal essential medium (MEM)–
10% FBS. Cells were incubated for 3 days, after which cells were fixed and
stained with crystal violet, and plaques were counted.
Complement reagents, proteins, and antibodies. NHS used in this
study was previously collected from healthy donors, processed, and di-
vided into small aliquots before being frozen at80°C as described pre-
viously (16). Purified human complement components C3b, C4b, factor
I, factor H, and C4bp were from Complement Technologies (Tyler, TX).
Purified soluble CD46 (sCD46) was purchased from Sino Biologicals
(Beijing, China). Soluble CR1 (sCR1) was a kind gift from Henry Marsh
(Celldex Therapeutics, Needham, MA). Goat polyclonal anti-human C3
was from Calbiochem (catalog no. 204869), mouse monoclonal anti-
CD46was fromR&D(catalog no.MAB2005), and goat anti-human factor
I was from Complement Technology (catalog no. A238).
Factor I protease assays. In vitro factor I-mediated cleavage activity
was assayed as described previously (11). In a standard assay, 5 g of
purified NiV particles derived from infected HeLa cells was incubated for
4 h in PBS (pH 7.4) at 37°C with 3 g of either C3b or C4b in a total
volume of 20 l. Positive-control samples contained 100 ng of purified
factor I. Except where indicated, standard reaction mixtures contained
factor H (1g), soluble CD46 (1g), C4BP (1g), or soluble CR1 (1g)
as cofactors. Reactions were stopped by adding 5l of SDS-PAGE sample
buffer containing mercaptoethanol and boiling. C3b reaction products
were analyzed on 9% SDS-PAGE gels, while C4b reaction products were
analyzed on 10% gels. The gels were stained with Gelcode blue stain re-
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agent (Thermo Scientific, IL) to visualize proteins. The level of intact C3b
= chain remaining after incubationwas quantitated using a Kodak Image
Station 4000R and compared to C3b = chain in standard reaction mix-
tures lacking cofactor (set at 100%).
Real-time PCR analysis. Total RNA was purified from 106 HeLa cells
using the RNeasy Plus purification system (Qiagen), with spectrophoto-
metric analysis showing very high RNA purity. One microgram of RNA
was used to generate cDNA using the Superscript III system (Invitrogen)
as described by the manufacturers. One-tenth of the cDNA reaction was
then used in real-time PCRs with primers specific for human factor I
(Hs00989715_m1; Life Technologies) and the Applied Biosystems Taq-
ManUniversal PCRmastermix. In parallel, 10-fold dilutions of a plasmid
encoding human factor I (kindly provided by Anna Blom, Lund Univer-
sity, Sweden) were analyzed to generate a standard curve with plasmid
copy number, and the HeLa cell copy number was calculated from the
corresponding threshold cycle (CT) values. No signals were generated
using control samples lacking RNA or which did not have reverse trans-
criptase added.
N-terminal protein sequencing. Protein sequence analysis was per-
formed using an Applied Biosystems model 492HT protein/peptide se-
quencer equipped with an online phenylthiohydantoin (PTH)-amino
acid analyzer according to the standardmethods for the instrument. Sam-
ples were introduced into the sample cartridge as blots on polyvinylidene
difluoride (PVDF)membranes previously stainedwith Coomassie blue to
detect the bands of interest. PTH-amino acids released at each cycle of
Edman degradation were identified by manual comparison of each chro-
matogram to the standard PTH-amino acid chromatogram run at the
start of the analysis.
ELISA and Western blotting. Purified NiV (0.01 g) in PBS was
mixed with a 1:10 dilution of NHS (assay volume, 20 l) and incubated
for 2 to 5 min at 37°C. The samples were further diluted 1:500 and ana-
lyzed using an OptEIA human C3a kit (BD Biosciences) as described by
the manufacturer.
ForWestern blotting, protein samples were separated on a 0.9% SDS-
PAGE gel and analyzed by Western blotting using rabbit polyclonal anti-
sera specific for CD46 (1:500 dilution; Santa Cruz Biotechnology, catalog
no. SC-9098). Alternatively, blots were probed with polyclonal goat anti-
sera (Santa Cruz Biotechnology, catalog no. SC-69470) or amousemono-
clonal antibody (R&D Systems, catalog no. MAB3307) specific for the
large and small fragments of factor I, respectively. Blots were visualized by
horseradish peroxidase-conjugated secondary antibodies and enhanced
chemiluminescence (Pierce Chemicals).
EM. C3 deposition on NiV was analyzed by adsorbing 0.5 g of puri-
fied virus on carbon-coated 200-mesh gold grids (CF200-Au; Electron
Microscopy Sciences, PA) followed by a 5-min incubation at room tem-
perature in a humidified chamber. After treatment with NHS (1:10 dilu-
tion) at 37°C, samples were blocked with 1% bovine serum albumin
(BSA) in PBS and then probed with anti-C3 monoclonal antibody (Cell
Sciences) at a dilution of 1 g in 10 l. Deposition was detected with
6-nm-diameter gold particle-labeled goat anti-mouse antibodies (Jackson
ImmunoResearch Laboratories, PA). To detect virion-associatedCD46 or
factor I, purified NiV was probed with mouse anti-human CD46 or goat
anti-human factor I followed by 12-nm-diameter gold particle-labeled
anti-mouse or donkey anti-goat (Jackson ImmunoResearch Laboratories,
PA), respectively. After labeling, particles were subjected to negative stain-
ing with 2% phosphotungstic acid (pH 6.6) and analyzed by electron
microscopy (EM) with a Technai transmission electron microscope.
RESULTS
NiV is resistant to complement-mediated neutralization in
vitro. We have previously shown that a wide range of negative-
strand RNA viruses are effectively neutralized in vitro by comple-
ment pathways. An example of this is shown in Fig. 1A for sera
from two individual donors, where incubation of PIV5 with NHS
for 1 h at 37°C resulted in complete neutralization (samples with
asterisks). In contrast, identical treatment with heat-inactivated
(HI) serum had no substantial effect on PIV5 infectivity. To de-
termine if NiV was similarly sensitive to complement-mediated
neutralization in vitro, infectious NiV was incubated under BSL4
conditions with PBS as a negative control, a serum containing
neutralizing antibodies as a positive control, or dilutions of NHS
or HI NHS. After 1 h at 37°C, the remaining infectivity was deter-
mined by plaque assay. As shown in Fig. 1B for a representative
donor serum, NiV was neutralized by the anti-NiV sera but
showed no loss of infectivity even with a 1:5 dilution of NHS.
These data indicate that unlike other paramyxoviruses we have
tested so far, NiV is refractory to complement-mediated in vitro
neutralization. In all subsequent biochemical experiments de-
scribed below, NiV was purified by sucrose gradient centrifuga-
tion, and infectivity was inactivated on dry ice by gamma irradia-
tion.
To determine if complement was activated by NiV, NHS was
incubated alone or with purified gamma-irradiated virus and
complement activation was assayed by an ELISA specific for the
C3a cleavage product. As seen in Fig. 1C, incubation of NiV with
serum resulted in appearance of C3a cleavage product in as little as
2min. Immunogold electronmicroscopy (Fig. 1D) showed exten-
sive deposition of C3 on serum-treated PIV5, consistent with our
prior finding that PIV5 activates complement (16) and with the
sensitivity of PIV5 to complement-mediated neutralization (Fig.
1A). In contrast, as shown in the two EM examples in Fig. 1D,
NHS-treated NiV particles showed very little C3 deposition.
While PIV5 and NiV were grown under different cell culture
conditions and in different laboratories, these data are consis-
tent with all of our prior results with PIV5 showing deposition
of complement. The PIV5 sample served as a control to visual-
ize what C3 deposition looked like for a virus that was sensitive
to complement and which contrasted with the lack of C3 de-
position on NiV particles. Taken together, these data indicate
that treatment of NiV with NHS activates complement path-
ways in vitro, but this does not result in extensive C3 deposition
or loss of infectivity.
NiV contains a factor I-like activity that functions with co-
factors to cleave C3b into iC3b in vitro. The = chain of C3b can
be cleaved by factor I protease when one of multiple cofactors is
present. As shown in the schematic in Fig. 2A, when factor I is
coupled with factor H, this cleavage can occur at two possible sites
in the = chain: R1281 and R1298 (sites 1 and 2 in Fig. 2A). In the
presence of CR1, factor I can cleave the= chain at sites 1 and 2 but
also at an additional site at R932 (site 3).
To determine if NiV could supply factors that result in inacti-
vation of C3b as seen for other paramyxoviruses, NiVwas isolated
from the media of infected HeLa cells by pelleting through a su-
crose cushion, followed by conventional sucrose gradient centrif-
ugation as described previously (11). As shown in the Coomassie
blue-stained gel in Fig. 2B (lanes 2 and 4), purification of NiV
resulted in an enrichment of virus as evidenced by the large
amounts of N, P, and F1 proteins and the fact that many of the
proteins from noninfected HeLa cells (lanes 1 and 3) were not
enriched during the purification process.
In vitro cleavage reactions were reconstituted using purified
complement components and purified NiV. After 4 h at 37°C,
proteins were analyzed by SDS-PAGE and Coomassie blue stain-
ing. As seen for the positive-control samples in Fig. 2C (lane 3),
incubation of theC3b substrate with factorH and factor I protease
Nipah Virus and Complement
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resulted in loss of the C3b = chain and appearance of the corre-
sponding 68- and 43-kDa fragments. Incubation of C3b with NiV
alone or with NiV plus factor I did not affect levels of the = chain
(lanes 4 and 6). Most importantly, addition of NiV along with
factor H but without any added factor I (lane 5) resulted in loss of
the C3b= chain to the same extent as the positive-control sample
(lane 3). Peptide sequencing (Table 1) revealed that the 43-kDa
cleavage product from the positive-control reaction mixture con-
taining factor I plus factor H (Fig. 2C,lane 3, band a) had the same
N-terminal amino acid sequence as the 43-kDa cleavage product
of NiV plus factor H (Fig. 2C, lane 5, band b). For NiV samples
(e.g., Fig. 2C, lanes 4 to 6), an additional protein species of un-
known origin was seen running with the dye front. These data
indicate that purified NiV has a “factor I-like” activity capable of
functioning with factor H to cleave C3b in vitro.
C3b can also be cleaved at three sites by factor I in the presence
of CR1 (Fig. 2A), resulting in a different cleavage pattern from that
seen with factor I plus factor H (Fig. 2D). When C3b was incu-
bated with purified NiV and a soluble version of CR1 (sCR1), a
43-kDa product was generated (Fig. 2D, lane 5). N-terminal pep-
tide sequencing (Table 1) revealed that this cleavage product from
the reaction mixture containing NiV plus sCR1 (Fig. 2D, lane 5,
band b) had the same amino acid sequence as the cleavage product
generated by the positive-control factor I plus CR1 (Fig. 2D, lane
3, band a). Interestingly, the reactions from NiV plus sCR1 gen-
erated cleavage of C3b= chain at sites 1 and 2 to produce only the
46- and 43-kDa products, respectively. However, the subsequent
cleavage at site 3 to generate the 40- and 25-kDa products did not
occur (Fig. 2D, compare lanes 3 and 5). Even overnight incubation
of NiV with C3b and sCR1 did not promote cleavage of the =
chain at site 3 (data not shown).
The extent of NiV-mediated cleavage of the C3b = chain was
dependent on the amount of virus added to the in vitro reactions,
but the sensitivity to virus concentration differed depending on
whether factor H or sCR1 was included as the cofactor (compare
Fig. 3A and B). This is evident in Fig. 3A for NiV plus factor H,
where 50% of NiV-mediated C3b = cleavage was seen with
less than 2 g of virus. In contrast,12 g of virus was needed
to obtain50% of C3b = cleavage when NiV was assayed with
sCR1 (Fig. 3B). Similarly, time course experiments showed that
NiV-mediated C3b = cleavage was rapid when factor H was
used as a cofactor (one of two representative experiments
shown in Fig. 3C), with50% of C3b = cleaved by40 min of
incubation. In contrast, = cleavage was relatively slow and
ineffective when sCR1 was used as a cofactor (Fig. 3D), with
50% of C3b = cleaved by 120 min of incubation. In addi-
tion, the dependence of NiV-mediated = cleavage on factor H
concentration differed from that seen with the positive control
FIG 1 Live NiV is not neutralized by NHS in vitro. (A and B) One hundred PFU of PIV5 (A) or NiV (B) was incubated with PBS as a control (Ctr [cross-hatched
bar]) or with dilutions of NHS (gray bars) or HI NHS (black bars) for 1 h at 37°C. In addition, one NiV sample contained a neutralizing anti-NiV antibody (Ab)
as a positive control. The remaining infectivitywas determined by plaque assay. Results represent the average of three assays, with error bars representing standard
deviations. Asterisks indicate that no plaques were detected in these samples. (C) NHS (1:20 dilution) was incubated at 37°C alone (gray bars) or with purified
NiV (black bars) for 2, 4, or 5min. Samples were analyzed by ELISA for levels of C3a. (D) Purified PIV5 orNiVwas applied to carbon grids and treated withNHS
as described in Materials and Methods. Samples were subsequently treated with mouse monoclonal anti-C3 followed by gold-conjugated goat anti-mouse
(12-nm-diameter beads) before examination by electron microscopy. The size bar indicates 0.1 m.
Johnson et al.
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of purified factor I, since 20-fold more factor H was needed
to drive 50% = cleavage using NiV rather than purified factor
I (data not shown).
Factor I protease can also function in C3b = cleavage by using
membrane-bound CD46 as a cofactor (6, 7). Western blotting
with anti-CD46 antibodies revealed that CD46 was associated
withNiV particles (Fig. 4A) and immunogold EMofNiV particles
showed extensive CD46 staining (Fig. 4B). Surprisingly, relative to
the positive control of factor I plus soluble CD46 (Fig. 4C, lane 3),
in vitro C3b = cleavage did not occur to a significant extent when
NiV was incubated with C3b alone (Fig. 4C, lane 4) or when reac-
tion mixtures were supplemented with additional soluble CD46
(Fig. 4C, lane 5). This result contrasts with our prior work show-
ing for VSV andmumps virus (MuV) that virion-associatedCD46
functions in C3b cleavage in vitro (11). It is noteworthy that addi-
tion of exogenous factor I to the reaction (Fig. 4C, lane 6) resulted
in a small amount of 43-kDa and 46-kDa cleavage products. This
indicates that NiV-associated factor I activity is unusual in that it
functions poorly in vitrowith virion-associated or soluble cofactor
CD46, but in addition, this shows that the activity of the virion-
associated CD46 cofactor is only evident when additional factor I
is supplied. This may reflect a need for higher levels of factor I
FIG 2 Purified NiV promotes factor H- and CR1-dependent cleavage of C3b. (A) The C3b = fragment is depicted as a box with vertical arrows denoting
three numbered sites of cleavage by factor I in the presence of either of the cofactors factor H (sites 1 and 2) or CR1 (sites 1, 2, and 3). The amino acid
sequences surrounding factor I cleavage sites at arginines 932, 1281, and 1298 and the apparent molecular masses (kDa) of cleavage products as seen on
SDS gels are shown. (B) Purified NiV (20 g and 5 g in lanes 2 and 4, respectively) and noninfected HeLa cell lysate (10 g, lanes 1 and 3) were analyzed
by SDS-PAGE and Gelcode blue staining. The positions of viral P, N, and F1 are indicated. Lane 1 is a marker lane with proteins of the indicated molecular
masses (kDa). (C and D) C3b = cleavage with cofactor factor H (C) or sCR1 (D) was reconstituted in vitro using the indicated purified proteins. After 4
h at 37°C, samples were analyzed by SDS-PAGE and Gelcode blue staining. The positions of the = and  chains of C3b and the cleavage products are
indicated. a and b denote the positions of bands excised from the gel for protein sequence analysis. The position of an 46-kDa intermediate cleavage
product is indicated to the right of panels C and D.
TABLE 1 Sequences of the peptides examined in this studya
Sample no. Gel-lane-band in Fig. 2 Cofactor protease Amino acid sequenceb
1 C-3-a Factor H factor I (control) Gly/Ser/Pro-Glu-Glu-Thr/Pro-Lys-Glu-Asn-Glu-Gly-Phe-Thr
2 C-5-b Factor H NiV Gly/Ser/Pro-Glu-Glu-Thr/Pro-Lys-Glu-Asn-Glu-Gly-Phe-Thr
3 D-3-a sCR1 factor I (control) Gly/Ser/Pro-Glu-Glu-Thr-Xxx-Glu-Asn-Glu-Gly-Phe-Thr
4 D-5-b sCR1 NiV Gly/Ser/Pro-Glu-Glu-Thr-Xxx-Glu-Asn-Glu-Gly-Phe-Thr
a C3b cleavage reactions with either factor H (samples 1 and 2) or sCR1 (samples 3 and 4) were reconstituted in vitro using the purified proteins indicated in Fig. 2C and D,
respectively. After 4 h at 37°C, samples were analyzed by SDS-PAGE, and the bands labeled a and b in Fig. 2 were processed for N-terminal protein sequencing as described in
Materials and Methods.
b Xxx indicates the presence of an amino acid that could not be clearly identified, and italic type indicates a possible residue in that position.
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when combined with CD46 versus that seen with factor H (see
above).
NiV-associated protease activity does not function in in vitro
cleavage of C4b. The C3 convertase C4bC2a can be inactivated by
factor I cleavage of C4b in the presence of cofactors CR1 or C4BP,
with cleavage occurring at two sites within the = chain: R937 and
R1318 (Fig. 5A). As shown in Fig. 5B (lane 3), in vitro reconstitu-
tion of C4b cleavage with purified factor I protease and sCR1
resulted in cleavage of the C4b = chain into C4d and a 25-kDa
fragment. However, incubation of C4b with NiV alone (lane 4) or
with NiV plus CR1 (lane 5) or factor I (lane 6) did not produce
significant cleavage of the C4b = chain. Similar results were seen
whenC4b cleavagewas reconstitutedwithC4BP as a cofactor (Fig.
5C), where no detectable loss of the C4b = chain was seen follow-
ing incubation with purified NiV. These data indicate that unlike
purified factor I protease, the NiV-associated protease cannot
function in in vitro cleavage of the C4b = chain.
Factor I is expressed byHeLa cells and is associatedwithNiV
particles. The NiV-associated factor I-like activity that cleaves
C3b could be derived from the infected HeLa cells. To confirm
that HeLa cells express factor I, two independent preparations of
HeLa RNA were reverse transcribed and then used in real-time
PCRs to quantitate levels of factor I RNA. Results from these sam-
ples were compared to those obtained from a standard curve gen-
erated from known copy numbers of a plasmid encoding human
factor I. As shown in Fig. 6A, approximately 5 	 102 to 1 	 103
copies of factor I RNA per 0.1 g of cellular RNA were found in
two separate preparations. In addition, Western blotting of HeLa
cell lysates with two different antibodies showed weak staining for
protein bands withmobilities matching those of the factor I heavy
and light chains (Fig. 6B). These data indicate that HeLa cells
express low levels of factor I as a possible source of protease during
NiV infections.
Attempts to detect NiV-associated factor I byWestern blotting
with polyclonal goat antiserum gave inconsistent results, due in
large part to high background on blotting membranes. As a more
sensitive method that can also show localization on virions, NiV
particles were analyzed by immunogold EM using polyclonal an-
tibody specific for factor I. As shown in Fig. 6C, NiV particles
showed low levels of staining for factor I, much of which was
localized to regions consistent with viral membrane structures.
These data are consistent with a proposal that NiV-associated fac-
tor I is present at low levels on virions but at high enough concen-
trations to function enzymatically against C3b.
We tested the hypothesis that the closely related henipavirus
HeV could also supply factor I-like activity. HeV was grown in
HeLa cells and purified by the same conventional sucrose gradient
centrifugation approaches used for preparation of NiV before un-
dergoing testing in in vitro cofactor cleavage assays. As shown in
Fig. 6D, overnight incubation of HeV with C3b and factor H as a
cofactor resulted in a small amount of C3b cleavage. These data
FIG 3 Concentration- and time-dependent C3b cleavage by purified NiV. (A and B) C3b cleavage reactions were reconstituted as described in the legend to Fig.
2 using the indicated components, including either factor H (A) or sCR1 (B) as a cofactor. After 4 h at 37°C, samples were analyzed by SDS-PAGE and Gelcode
blue staining. Levels of C3b = chain remaining in the cleavage reactions were quantitated as a function of NiV concentration and compared to the level of = in
a control sample containing C3b and factor I without cofactor set to 100%. (C and D) C3b cleavage reactions were reconstituted using 10 g of NiV along with
2 g of either factor H (C) or sCR1 (D). After incubation for the indicated times at 37°C, samples were analyzed by SDS-PAGE as described for panels A and B.
Data in panels C and D are representative of two independent experiments.
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indicate thatHeVprovides a low level of factor I activity compared
to that seen with NiV.
DISCUSSION
Many viruses block steps in the complement cascade, with inhibi-
tion often focused at the level of formation or stability of the C3
convertase (9, 10). Given our prior findings that most paramyxo-
viruses are sensitive to complement-mediated neutralization (11,
15) and that NiV replication and dissemination involve exposure
to environments rich in complement factors, we have tested
whether the emerging pathogen NiV is neutralized by NHS in
vitro. Under BSL4 conditions, we demonstrate here that NiV is
refractory to neutralization with high concentrations of NHS, a
result that contrasts with our results on other enveloped RNA
viruses (e.g., PIV5, NDV, MuV, and VSV). Furthermore, C3 is
activated in vitro by exposure toNiV, but in contrast tomost other
paramyxoviruses, there is no evidence of extensive C3 deposition
on NiV particles. Our most striking findings are that purified NiV
can supply a cofactor-dependent factor I protease activity in func-
tional C3b cleavage reactions in vitro and that NiV particles stain
with antibodies to factor I. These results support a novel mecha-
nism of complement evasion by NiV through C3b inactivation by
a factor I-like protease.While there is a single prior report of factor
I associationwith theGram-negative pathogen Prevotella interme-
dia (28), our work is the first evidence of a functional factor I-like
activity with a viral pathogen.
Our previously published work showed that VSV-based pseu-
dotypes containing the NiV glycoproteins were highly resistant to
in vitro complement-mediated neutralization and that serum-
treated pseudotypes showed no significant C3 deposition (27). As
a more rigorous test, we have examined complement interactions
with bona fide NiV. Together, these results raise the proposal that
factor I is recruited to the NiV surface through interactions with
one or both of the viral glycoproteins. NiV encodes two integral
transmembrane proteins that are synthesized in the exocytic path-
way and are expressed at the infected cell surface: a fusion protein
(F) that promotes membrane fusion and the attachment glyco-
protein (G) that binds the highly conserved cellular receptors eph-
rins B2 and B3 (29, 30). Factor I is synthesized as a secreted pre-
cursor by a variety of cell types and is transported through the
exocytic pathway to accumulate in extracellular fluids at relatively
low concentrations (6, 7, 31). This suggested that factor I is pro-
duced by HeLa cells, and at some point in its biosynthesis and
transport through the exocytic pathway, the protease becomes
associated with the NiV glycoproteins. Consistent with this pro-
posal, we show that naive HeLa cells express low levels of factor I
RNA and protein. Furthermore, NiV infection has been shown to
induce a number of cytokines, such as interleukin-6 (IL-6), which
are known to upregulate factor I synthesis (32). This raises the
possibility that factor I levels are increased followingNiV infection
and this leads to enhanced association with NiV particles. Future
BSL4 work will test this hypothesis in cells with alterations to
factor I biosynthesis and in relevant cell types, such as human
respiratory cells, or in animal models.
FIG 4 Soluble CD46 is a poor cofactor for NiV-mediate C3b cleavage. (A) The indicated amounts of purified NiV were analyzed by Western blotting for the
presence of CD46. Recombinant CD46 (0.5 g) was analyzed as a positive control. (B) Purified NiV was applied to carbon grids and treated with mouse
monoclonal antibody to CD46 followed by gold-conjugated anti-mouse (12-nm-diameter beads) before examination by electron microscopy. Two represen-
tative virions are shown, with the size bar indicating 0.1 m. (C) C3b cleavage reactions were reconstituted using the indicated components plus sCD46 as a
cofactor. After 4 h at 37°C, samples were analyzed as described in the legend to Fig. 2.
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As an alternative hypothesis, it is formally possible that the
particles containing the NiV glycoproteins (NiV particles and
VSV pseudotypes) have inherent protease activity capable of the
same high specificity for C3b cleavage sites and cofactor depen-
dence as those seen with factor I. Computer-generated sequence
alignment has failed to reveal evidence of significant homology
between the NiV F or G proteins and human factor I (not shown),
although it is conceivable that a three-dimensional folding of one
or both of theNiV glycoproteins could create a protease active site
with high specificity similar to factor I.
In the presence of factor H or sCR1, purified NiV supplied a
protease activity that was capable of cleaving C3b at the same sites
known to be processed by bona fide factor I. However, these func-
tional in vitro assays also showed that the cofactor requirement for
NiV-associated protease activity was not identical to that seen
with purified factor I. This was evident by the finding that while
NiV protease activity was very effective in in vitro cleavage of C3b
when factor H was used, this cleavage event required higher levels
of factor H than were seen with purified factor I. Similarly, the
NiV-associated cleavage of C3b differed from that of purified fac-
tor I by the relatively low activity when coupled with sCR1 as a
cofactor and in that only the first two of three possible C3b cleav-
age sites were processed. In this regard, this incomplete processing
of C3b by NiV factor I protease is still sufficient to inactivate the
function of the C3 convertase, as has been shown in previous
studies with vaccinia virus complement control protein VCP (13).
Finally, there was no detectable NiV-mediated C3b cleavage activ-
ity seen with soluble or virion-associated CD46 or when NiV was
assayed in vitro against C4b as a substrate. Together, these data
indicate that the NiV-associated factor I activity differs function-
ally from that of soluble factor I.
What is the basis of the unusual cofactor requirements and
substrate specificity for thisNiV-associated protease? Factor I is an
88-kDa serum protein composed of a series of linked modular
domains: a factor I-membrane attack complex (FIMAC) domain,
one CD5 domain, two low-density lipoprotein receptor (LDLr)
domains, and one serine protease (SP) domain (6, 7, 31). Struc-
tural and modeling data suggest that surface-exposed regions of
these factor I domains combine to form one part of a tripartite
structure along with one of the cofactors and either C3b or C4b as
the substrate (6, 33). Formation of this tripartite complex (factor
I-substrate-cofactor) is thought to cause a conformational change
in factor I such that the catalytic site is then active and able to
cleave C3b or C4b. At this time, it is unclear how the NiV-associ-
ated factor I protease is bound to the virion particle. However, one
possibility is that the tethering of factor I protease to the NiV
surface may be through binding to one or more of these key mod-
ule domains, resulting in restricted access to some but not all
substrates and associated cofactors. Thus, the finding that factorH
was the most potent at stimulating C3b cleavage by NiV factor I
could reflect an easier accessibility of a tethered protease to this
particular cofactor or a difference in cofactor-induced conforma-
tional changes when binding C3b versus C4b substrates.
As an additional variable, the cofactors that modulate factor I
activity can be soluble (e.g., factor H) or membrane bound (CR1,
CD46, and C4BP), and the finding that the soluble factor H was
the most potent cofactor for the NiV protease suggests that this
factor could also contribute to differences between NiV protease
and soluble factor I. It is also possible that the preferred use of
factor H versus other cofactors (e.g., CD46 or CR-1) could reflect
the overall size, sequence, or structure of the different cofactors. In
this regard, the factor I-associated cofactors are characterized by
FIG 5 NiV does not promote cofactor-dependent cleavage of C4b. (A) The C4b = fragment is depicted as a box with vertical lines denoting two numbered sites
of cleavage by factor I in the presence of either CR1 or C4BP. The amino acid sequences surrounding the two factor I cleavage sites at arginines 937 and 1318 and
the apparent molecular masses of cleavage products as seen on SDS gels are shown. (B and C) C4b cleavage reactions with cofactors sCR1 (B) or C4BP (C) were
reconstituted in vitro using the indicated purified proteins. After 4 h at 37°C, samples were analyzed by SDS-PAGE and Gelcode blue staining. The positions of
the C4b =, , and 
 chains, and the C4d and 25-kDa cleavage products are indicated.
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having various numbers of tandemly repeated 60-amino-acid-
long complement control protein (CCP) modules: 30 CCPs for
common alleles of CR1, 20 CCPs for factor H, 3 or 8 CCPs for the
two chains of C4BP, and 4 CCPs for CD46 (7). Future studies will
determine the contributions of virus tethering, soluble versus
membrane-bound cofactors, and the cofactor CCP modules in
determining the unique cleavage specificity of NiV-associated fac-
tor I activity.
When purified HeV was tested in functional assays for in vitro
C3b cleavage, only very low levels of factor I-like protease activity
were detected. This suggests that the NiV and HeV glycoproteins
may differ in their ability to recruit factor I from serum or from
within infected cells. The NiV and HeV F and G proteins are very
closely related, but the finding of distinct areas of divergence in
amino acid sequencemay provide a tool to dissect themechanism
of factor I recruitment. The implications of differences in factor I
recruitment on NiV and HeV pathogenesis will require further
work in animal models.
In conclusion, we have identified a novel mechanism by which
NiV evades the human complement system through a factor I-like
protease activity. Disruption of the ability of NiV to recruit com-
plement inhibitors could form the basis for the development of
safer vaccines or more effective therapies to combat these highly
pathogenic emerging viruses.
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